Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DE-120 + aflibercept
- Development stage
- Unknown
- Lead developer
- Santen Pharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravitreal
01
Overview
DE-120 + aflibercept is an investigational combination therapy under clinical evaluation for neovascular (wet) age-related macular degeneration (AMD). DE-120 is a small molecule dual tyrosine kinase receptor inhibitor that targets both vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) signaling pathways, disrupting angiogenesis in the retina. Aflibercept is a recombinant fusion protein (commonly marketed as Eylea) that acts as a high-affinity decoy receptor for VEGF-A, VEGF-B, and placental growth factor (PlGF), preventing these ligands from activating their endogenous receptors and thus inhibiting pathological blood vessel formation. The combination aims to provide a synergistic antiangiogenic effect and potentially improve long-term visual outcomes in patients with subfoveal choroidal neovascularization secondary to AMD. DE-120 is developed by Santen; aflibercept is developed and commercialized by Regeneron and Bayer[1][3][4][5][7].
- Other names
- aflibercept
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PGF (Placental Growth Factor)PDGFR (PDGFR family)VEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)VEGFR-1 (Vascular endothelial growth factor receptor 1)
Beyond the preview
Go deeper on DE-120 + aflibercept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DE-120 + aflibercept.